_____________________________________________________________________________________ Paxman
Scalp Cooling
Beyond efficiency, it is also about making our people’ s work valuable
infusion, throughout the treatment itself, and for around 90 minutes afterwards. The cooling process works on several levels. First, it induces vasoconstriction, reducing the flow of chemotherapy drugs to the scalp and protecting the hair follicles from their negative effects. Secondly, it produces a drop in metabolic rate, which slows cell division and further reduces the targeted effect of the treatment on hair cells. Paxman explored the science behind this in collaboration with universities, including through cell culture models, studying hair cells in vitro, which have demonstrated that less drug diffuses through the cell membrane, both actively and passively. In other words, through the use of the scalp cooling system, less
of the drug is entering the cell and causing damage through the various mechanisms by which chemotherapy operates.
Committed to offering the best solution for cancer patients, Paxman recently joined forces with Dignitana, its main competitor, through an acquisition. It offered clear synergies and economies of scale, and while Dignitana had faced challenges, it brought with it an impressive customer base and team. Thus, merging the two businesses made complete sense. Paxman began exploring this opportunity at the end of 2024, before completing its due diligence in mid-2025 and making a formal offer in the second half of the year, which was accepted.
“ We spent most of the end of 2025 integrating both businesses, which has been
manufacturing-today. com 113